Johnson & Johnson MedTech, a prominent player in cardiac arrhythmia treatment, is set to unveil new clinical and real-world data from its VARIPULSETM Platform, designed for pulsed field ablation (PFA) procedures addressing atrial fibrillation (AF). This presentation will occur during the Asia Pacific Heart Rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS) joint annual meeting, taking place from November 12 to 15, 2025, in Yokohama, Japan.
The VARIPULSETM Platform is an integrated system that includes the VARIPULSETM Catheter, TRUPULSETM Generator, and CARTOTM 3 Mapping System VARIPULSETM Software. It has received approval for use in multiple regions, including the United States, Europe, Asia Pacific, Canada, and Latin America. To date, over 25,000 procedures have been performed using this platform across various countries, including the U.S., Japan, and several others in Asia and Oceania.
“The clinical evidence we are presenting at this year”s APHRS and JHRS highlights the comprehensive capabilities of our CARTOTM 3 Mapping System and VARIPULSETM Platform for pulsed field ablation,” stated Jing Li, Vice President of Electrophysiology & Neurovascular for Asia Pacific MedTech at Johnson & Johnson. “Our commitment to advancing scientific knowledge and improving patient outcomes is reflected in our robust scientific program and educational sessions planned for the event.”
Key presentations will include findings from various studies such as QUEST AF, which focuses on the initial real-world experiences with a high-power short-duration radiofrequency catheter for persistent atrial fibrillation ablation. Other notable presentations will cover topics like the impact of age and diagnosis-to-ablation time on outcomes following catheter ablation, as well as procedural characteristics linked to same-day discharge after pulsed field ablation treatment.
Furthermore, Johnson & Johnson MedTech aims to foster collaboration within the clinical community to enhance real-world evidence surrounding the VARIPULSETM Platform and expedite patient-centered innovations in atrial fibrillation care. The organization is committed to addressing significant health challenges globally through its advancements in cardiovascular solutions.
For additional details about Johnson & Johnson”s MedTech innovations and the upcoming presentations, interested parties can visit thenext.jnjmedtech.com.
